Aignostics is a Berlin-based AI company that turns complex multimodal pathology data into insights for biopharma drug development and precision medicine. It started in 2018 within Charité Berlin and the Berlin Institute of Health, spun out of Charité in 2020, and operates offices in Berlin and New York.

Its products include PathoSearch, a visual search engine that retrieves diagnosed reference cases with similar morphology, and Atlas H&E-TME, a tumor microenvironment profiling application for H&E whole slide images powered by the Atlas 2 foundation model co-developed with Mayo Clinic. It also offers pathology foundation models for embeddings and custom applications. Services cover target and biomarker discovery, translational research and digital diagnostics. A joint Target ID Platform with Bayer integrates proteomics, transcriptomics, epigenomics and imaging data into a multimodal AI model.

Aignostics says it has access to pathology samples and multimodal data from over 30M patients at leading university hospitals and laboratories. The company reports 120+ employees, ISO 13485 and ISO 27001 certification, and a GCP-ready clinical trial platform. It has raised over $55M in total, including a $34M Series B led by ATHOS in October 2024.